Welcome to our dedicated page for Prime Medicine SEC filings (Ticker: PRME), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Prime Medicine, Inc. SEC filings document the biotechnology company's financial results, pipeline disclosures, governance matters and material events tied to its Prime Editing programs. Recent Form 8-K filings include Item 2.02 results releases, Regulation FD corporate presentations and Item 5.02 executive appointment disclosures, with exhibits summarizing business highlights for PM577 in Wilson Disease, PM647 in Alpha-1 Antitrypsin Deficiency and PM359 in chronic granulomatous disease.
Proxy materials disclose annual meeting matters, director elections, auditor ratification, executive compensation and equity-plan information. Together, the filings provide formal records of PRME's public-company governance, disclosure controls, capital and compensation arrangements, and regulatory-development communications for its genetic-medicine pipeline.
Prime Medicine, Inc. furnished a corporate update through a new investor presentation posted on its website on September 8, 2025. The company made the presentation, dated September 2025, available as Exhibit 99.1 to this report under a Regulation FD disclosure item.
The material is being treated as furnished, not filed, which means it is not subject to certain liability provisions of the Exchange Act and is not automatically incorporated into other securities law filings unless specifically referenced.
ARCH Venture group and certain affiliated funds and individuals report collective beneficial ownership of 18,486,894 shares of Prime Medicine common stock, representing 10.4% of the outstanding class on the basis described in this filing. The disclosure aggregates holdings across multiple ARCH entities and related partnerships and shows shared voting and dispositive power over those shares.
The filing also discloses that AVF XII purchased 3,030,300 shares at $3.30 per share in a public offering, for total consideration of $9,999,990, funded from AVF XII working capital. The amendment was filed because an issuer offering (an August 2025 issuance of 43,700,000 shares) changed the Reporting Persons' percentage ownership by one percent or more. The statement notes existing registration rights under an Amended and Restated Investors' Rights Agreement and that no Reporting Person was subject to disqualifying legal proceedings in the prior five years.
Prime Medicine (PRME) – Q2 2025 10-Q Snapshot
- Revenue: $1.1 m collaboration revenue (none in Q2 24); H1 revenue $2.6 m (+335% YoY).
- Expenses: R&D $41.4 m (-4% YoY); G&A $13.1 m (+4%). Total op-ex $54.5 m; loss from operations $53.4 m.
- Net loss: $52.6 m or $0.41/sh vs $55.3 m ($0.46) prior-year; H1 loss $104.5 m.
- Liquidity: Cash & cash equivalents $53.8 m (-70% YTD); investments $48.0 m; total liquid resources $101.8 m. Post-period Aug-25 equity raise added net $138.2 m, giving management >12-month runway.
- Balance sheet shifts: Right-of-use assets up to $120.2 m and non-current lease liabilities to $112.5 m following new Cambridge & Watertown facilities. Stockholders’ equity fell to $60.9 m (vs $153.1 m YE24) on continuing losses.
- Strategic updates: Focus pivots to in-vivo liver programs (Wilson’s, AATD) targeting INDs 1H-26; additional $24 m funding commitment from Cystic Fibrosis Foundation, incl. $6 m equity.
- Risks: Ongoing arbitration with Beam Therapeutics over AATD program could impose damages or halt development; high cash burn (~$90 m H1) and dilution from stock issuance remain concerns.
Management believes current cash plus August offering funds operations through at least Q3 26 while programs advance toward first clinical filings.
Chief Technical Officer Ann L. Lee filed a Form 4 showing a one-time repricing of 361,990 stock options originally granted under Prime Medicine’s 2019 and 2022 equity plans. On 08-01-2025 shareholders approved lowering the exercise price of the affected options from $12.30 and $8.49 to $4.04, the closing share price on the repricing date.
- Each original grant (180,995 options expiring 03-31-2033 and 180,995 options expiring 02-21-2034) was cancelled (coded “D”) and immediately re-granted (coded “A”) at the new strike.
- No change in the total number of options or underlying common shares; ownership remains 361,990 options, direct.
- All other terms, including vesting schedules, remain unchanged.
The filing signals management’s desire to restore the retention and incentive value of underwater options after PRME’s share price decline. While it is cash-neutral and non-dilutive today, repricing can draw shareholder-rights scrutiny because it rewards executives for past price under-performance without imposing new performance hurdles.